PACAP
- Category
- Brain & Cognition
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
PACAP is a naturally occurring 38-amino-acid neuropeptide marketed for neuroprotection after stroke and brain injury. Evidence is almost entirely animal-based: moderate data show reduced stroke damage, while Parkinson's and Huntington's claims rest on weaker findings, and human evidence is essentially absent. Its mechanism reliably triggers migraine and low blood pressure. Not an approved drug in the US; supply is unregulated research-grade material.
Read Full recordStudied uses & evidence
Studied uses(6)
Potent neuroprotection against ischemic brain injury (40-60% infarct reduction in animal models)
MediumConsistently reduces stroke damage in rodent models over 25 years of study; no human trials exist.
Protection of striatal neurons in Huntington's disease models via PAC1R/ERK/Akt signaling
LowProtects striatal neurons in a small number of Huntington's mouse studies; no human data.
Anti-apoptotic effects via Bcl-2 upregulation and cytochrome c suppression
MediumWell-replicated mechanism in animal and cell studies; not yet confirmed as a clinical benefit.
Evidence limits
- Evidence Level
- Strong Preclinical / Early Clinical
PACAP has an exceptionally strong preclinical evidence base with >3,000 publications demonstrating neuroprotection across stroke, traumatic brain injury, neurodegeneration, and retinal disease models. Clinical research has primarily focused on PACAP's role in migraine pathophysiology, where it has been validated as a therapeutic target. Anti-PACAP-ligand antibody LY3451838 (Eli Lilly) completed Phase 2 for migraine prevention. Direct therapeutic use of PACAP for neuroprotection has not yet entered clinical trials due to challenges with delivery and its vasodilatory/migraine-triggering side effects.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(3)
Risks = level of concern: High · Moderate · Low · Theoretical
Migraine/headache induction via vasodilation
HighSystemic vasodilation and hypotension
ModerateVery short half-life limiting therapeutic window
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.